Browse Category

ASX:CSL.AX 7 January 2026 - 26 February 2026

CSL share price edges up as buyback keeps ASX heavyweight in play
CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL announced Tuesday that Chief Executive Paul McKenzie is stepping down, with Gordon Naylor stepping in as interim CEO and managing director beginning Feb. 11. McKenzie, who came aboard as chief operating officer in 2019, moved up to the CEO post in March 2023. During his tenure, CSL rolled out new treatments, including Hemgenix, its gene therapy for haemophilia B. Naylor, previously finance chief and head of the Seqirus vaccines division, took a board seat in December.
CSL share price rebounds as inflation cools; ASX:CSL turns to February results and RBA call

CSL share price rebounds as inflation cools; ASX:CSL turns to February results and RBA call

CSL Ltd shares closed up 1.0% at A$170.00 on Wednesday. The biotech heavyweight recovered some ground after sliding 2.4% in the prior session as Australian stocks steadied after a softer inflation reading. The stock traded between A$168.65 and A$170.52 and is down about 41% over the past year, hovering near its 52-week low of A$168.00. Investing.com Australia
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Constellation Energy

NASDAQ: CEG 94 / 100
#3 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 92 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

AIG

NYSE: AIG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.